Furthermore, after adjusting for stage, histology, EGFR mutation, age, smoking, and surgery, multivariate analysis revealed that lung cancer patients with greater blood IGFBP2 had a worse survival result, with a hazard ratio of 8.22 (95% CI 1.78–37.92, p = 0.007) [112]. This evidence concerns the gene EGFR and lung cancer.